Mar 24 2023 |
PCAOB Enforcement Activity—2022 Year in Review [PODCAST] |
Cornerstone Research |
Mar 24 2023 |
U.S. Executive Branch Update – March 24, 2023 |
Squire Patton Boggs (US) LLP |
Mar 24 2023 |
The RESTRICT Act: A Potential New Enforcement Tool to Address Economic and National Security Concerns Posed by Foreign Information and Communications Technologies |
Bradley Arant Boult Cummings LLP |
Mar 24 2023 |
Judge Approves $25M Settlement of Antitrust Action Against J&J for Allegedly Blocking Biosimilars |
MoginRubin |
Mar 24 2023 |
EPA Proposes Enforceable Drinking Water Standards For PFAS |
Robinson & Cole LLP |
Mar 24 2023 |
USCIS Issues Guidance on Employers’ Ability to Pay Proffered Wage to Support Employment-Based Immigrant Petitions |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
Mar 24 2023 |
Pfizer Expands Cancer Drug Portfolio with $43 Billion Biotech Acquisition |
MoginRubin |
Mar 24 2023 |
Private Market Talks Episode 3: Canvassing the Credit Landscape with Carlyle's Justin Plouffe |
Proskauer Rose LLP |
Mar 23 2023 |
CIT Upholds List 3 and 4 Section 301 Tariffs |
Polsinelli PC |
Mar 23 2023 |
FTC Increases Scrutiny of Negative Option Marketing |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 23 2023 |
Non-Clarified – The NLRB GC’s McLaren Macomb Memo Provides Murky and Ominous Guidance on Board’s Prohibitions on Non-Disparagement and Non-Disclosure Provisions |
Epstein Becker & Green, P.C. |
Mar 23 2023 |
AI and Copyright: A New Kind of Copyright Troll? The Rise of AI in Creative Works |
Blank Rome LLP |
Mar 23 2023 |
NLRB’s General Counsel Issues A Memorandum In Light Of The McLaren Macomb Decision Addressing Severance Agreements Containing Broad Confidentiality and Non-Disparagement Terms (US) |
Squire Patton Boggs (US) LLP |
Mar 23 2023 |
APHIS Accepting Public Comments on Draft Guide for Submitting Permit Applications for Microorganisms Developed using Genetic Engineering |
Bergeson & Campbell, P.C. |
Mar 23 2023 |
THE CFPB WANTS IN ON THE DATA BROKER ACTION: With a Request for Information from the public |
Troutman Amin, LLP |
Mar 23 2023 |
PTO Deductions Are Not “Salary” Under the FLSA, Third Circuit Holds |
Jackson Lewis P.C. |
Mar 23 2023 |
No One Likes a Sore Winner: IPR Prevailing Party Can’t Appeal |
McDermott Will & Schulte LLP |
Mar 23 2023 |
Is SCOTUS Looking to Change the Enablement Requirement for Patents? |
Bradley Arant Boult Cummings LLP |
Mar 23 2023 |
[Podcast]: DOL’s 2022 Final ESG Rules |
Proskauer Rose LLP |
Mar 23 2023 |
Energy & Sustainability Litigation Updates — March 2023 |
Mintz |
Mar 23 2023 |
How to Succeed in Environmental Marketing Claims |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 23 2023 |
Energy & Sustainability IP Updates — March 2023 |
Mintz |
Mar 23 2023 |
NFT Service Brings Litigation Into the Metaverse! |
Hunton Andrews Kurth |
Mar 23 2023 |
April 2023 Visa Bulletin – Slight Thaw for EB-3 China, Retrogression for EB-2 India and Rest of World |
Hunton Andrews Kurth |
Mar 23 2023 |
Private Market Talks Episode 2: Driving Alpha with AB Private Credit Investors’ Brent Humphries |
Proskauer Rose LLP |
Mar 23 2023 |
FBI, CISA + MS-ISAC Warn of LockBit 3.0 Ransomware |
Robinson & Cole LLP |
Mar 23 2023 |
Essential LinkedIn Tips for Lawyers to Stand Out |
Bill4Time |
Mar 23 2023 |
SEC Proposes Safeguarding Rule Amending Custody Rule |
ArentFox Schiff LLP |
Mar 23 2023 |
Four Ways to Get Lawyers More Engaged in Using Your CRM System |
CLIENTSFirst Consulting |
Mar 23 2023 |
Private Market Talks Episode 1: Navigating Headwinds in Private Credit with KKR’s Dan Pietrzak |
Proskauer Rose LLP |
Mar 23 2023 |
Energy & Sustainability M&A Activity — March 2023 |
Mintz |
Mar 23 2023 |
SEC Advances Three New Cybersecurity Rule Proposals |
Hunton Andrews Kurth |
Mar 23 2023 |
NLRB General Counsel Releases Memo Concerning Confidentiality and Non-Disparagement Clauses in Severance Agreements Post-McLaren |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 23 2023 |
Senate Committee Hearing on EPA’s Proposed FY 2024 Budget Addresses TSCA, PFAS |
Bergeson & Campbell, P.C. |
Mar 23 2023 |
FDA Revises Recommendations Regarding Electronic Systems, Records, and Signatures in Clinical Investigations |
Nelson Mullins |